Oculis Holding AG (NASDAQ: OCS) Advances Eye Disease Treatments, Maintains Buy Rating

• H.C. Wainwright has reiterated its Buy rating for Oculis Holding AG, with shares trading at $7.49.
• Oculis is progressing with clinical trials for two key drug candidates: Privosegtor for acute optic neuritis and licaminlimab for dry eye disease.
• Initial results from the PREDICT-1 registrational trial for licaminlimab are anticipated around the end of 2026.

Oculis Holding AG (NASDAQ: OCS) is a biotechnology company developing innovative treatments for various eye diseases. H.C. Wainwright maintains its Buy rating on October 21, 2026, when the shares trade at $7.49. This positive rating comes as Oculis advances clinical trials for two key drug candidates, Privosegtor and licaminlimab, targeting significant ophthalmic conditions.

Oculis announced that new analyses from its Phase 2 ACUITY trial of Privosegtor are scheduled for presentation at the 10th Joint ACTRIMS-ECTRIMS Meeting in Toronto, held October 21–23, 2026, as highlighted by GlobeNewswire. This clinical trial focuses on patients suffering from acute optic neuritis, a debilitating condition characterized by inflammation of the optic nerve.

These upcoming analyses will delve into specific blood markers associated with nerve damage and inflammation. Such biomarkers are crucial for researchers to accurately assess disease progression and the therapeutic effects of potential treatments. Oculis has not yet disclosed the new results in its announcement, making the upcoming presentation a highly anticipated source of detailed information.

Furthermore, Oculis has successfully completed randomization in PREDICT-1, a registrational trial evaluating licaminlimab as a treatment for dry eye disease, as reported by GlobeNewswire. Randomization is the process of assigning patients to different treatment groups. Notably, approximately two-thirds of the 176 enrolled patients possess a specific genetic variant that has been correlated with a stronger therapeutic response in previous trials. Oculis anticipates releasing initial results from this pivotal study around the end of 2026.

Oculis estimates that approximately 1.5 million U.S. patients suffer from the specific form of dry eye disease that licaminlimab aims to treat. Currently, OCS shares trade at $7.49, reflecting an increase of $0.17, or 2.32%, with a trading volume of 318,463 shares. The company's market capitalization, representing the total value of its outstanding shares, stands at approximately $461.30 million. Over the past year, the stock has traded within a range of $7.11 to $34.48.